Brief: Sangamo Therapeutics & Astellas Enter Capsid License Agreement
19/12/2024 07:35
Dec 19 (Reuters) - Sangamo Therapeutics Inc SGMO.O &
Astellas Pharma Inc 4503.T :
* SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE
AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES
* SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION
IN
MILESTONE PAYMENTS
* SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT
LICENSE FEE
Source text: ID:nBw8WQ71Ra
Further company coverage: 4503.T
((Reuters.Briefs@thomsonreuters.com))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn